Hypertension, alone or with other antihypertensive agents. It can be used as initial therapy.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Amlodipine has a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.
Angiotensin II formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE), is a potent vasoconstrictor, the primary vasoactive hormone of the Renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex.
Olmesartan Medoxomil blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues, (e.g. vascular smooth muscle, adrenal gland). In vitro binding studies indicate that Olmesartan Medoxomil is a reversible, competitive inhibitor of the AT1 receptor. Olmesartan Medoxomil does not inhibit ACE (kinase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin).
One tablet (5/20 mg) once daily. Maximum dose two tablets (10/40 mg) once daily. May be taken with or without food.
The antihypertensive effect of angiotensin II receptor antagonists, including Olmesartan Medoxomil may be attenuated by NSAIDs including selective COX-2 inhibitors. Blood pressure, renal function and electrolytes should be closely monitored in patients on combination therapy and other agents that affect the RAS.
Hypersensitivity to any of the components of this combination product. When pregnancy is detected, this combination drug should be discontinued as soon as possible. therapy. Exercise caution: when administeringSymptomatic hypotension may occur after initiation of this combination, particularly in patients with severe aortic stenosis. Patients may develop increased frequency, duration or severity of angina or acute MI on starting calcium channel blocker therapy or at the time of dosage increase. Patients with Congestive Heart Failure: Calcium channel blocker should be used with caution in patients with Impaired Renal Function / Hepatic Impairment/congestive heart failure. No significant drug interactions have been observed when used individually or in combination.
Edema, dizziness, flushing, palpitation, vomiting, diarrhoea, rhabdomyolysis, alopecia, pruritus, urticaria etc
There is no information on over dosage in humans.
Store below 30∞C. protect from light. Keep this medicine out of reach of children.
.png&w=384&q=75)